Vector Science signs amended 10-year cGMP manufacturing deal with LyoGenesis

Reuters2026/08/17 11:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vector signed an amended, 10-year manufacturing and testing agreement with LyoGenesis, effective Aug. 13, 2026.
Deal secures exclusive, U.S.-based cGMP capacity for Vector’s lyophilized peptide pharmaceutical products at LyoGenesis’ Mequon, Wisconsin facility.
Verlytix will handle quality assurance inspections before batch release; product title transfers to Vector on delivery.
Contract renews automatically in one-year terms after the initial decade; financial terms were not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vector Science and Therapeutics Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608170745PR_NEWS_USPR_____LA27298) on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vector Science signs amended 10-year cGMP manufacturing deal with LyoGenesis

You may also like

Crypto prices